Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling

International Journal of Oncology

Volumn 31, Issue 3, 2007, Pages 593-600

  Yang, Yang ^a   Ikezoe, Takayuki ^b   Zheng, Zhixing ^a   Taguchi, Hirokuni ^b   Koeffler, H Phillip ^c   Zhu, Wei Guo ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b KOCHI MEDICAL SCHOOL   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Androgen receptor; Prostate cancer; PSA; Saw Palometto; STAT 3

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; INTERLEUKIN 6; PLANT EXTRACT; PROSTATE SPECIFIC ANTIGEN; SABAL EXTRACT; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ANIMAL; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANDROGEN ANTAGONISTS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PLANT EXTRACTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 38449120751     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.3.593     Document Type: Article

References (36)

1. Quigley CA, DeBellis A, Marschke KB, el-Awady MK, Wilson EM and French FS: Androgen receptor defects: historical, clinical, and molecular perspectives. Endocr Rev 16: 271-321, 1995.
2. Gelmann EP: Molecular biology of the androgen receptor. J Clin Oncol 20: 3001-3015, 2002.
3. Polascik TJ, Oesterling JE and Partin AW: Prostate specific antigen: a decade of discovery - what we have learned and where we are going. J Urol 162: 293-306, 1999.
4. Pang S, Dannull J, Kaboo R, Xie Y, Tso CL, Michel K, deKernion JB and Belldegrun AS: Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 57: 495-499, 1997.
5. Huang W, Shostak Y, Tarr P, Sawyers C and Carey M: Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem 274: 25756-25768, 1999. (Pubitemid 29418607)
6. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG and Henderson DR: Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 271: 7043-7051, 1996.
7. Ihle JN: STATs and MAPKs: obligate or opportunistic partners in signaling. BioEssays 18: 95-98, 1996. (Pubitemid 126599924)
8. Darnell JE Jr: STATs and gene regulation. Science 277: 1630-1635, 1997.
9. Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS and Tweardy DJ: Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 102: 1385-1392, 1998.
10. Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez- Luna JL, Nunez G, Dalton WS and Jove R: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10: 105-115, 1999.
11. Buettner R, Mora LB and Jove R: Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954, 2002.
12. Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R and Loughran TP Jr: Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest 107: 351-362, 2001.
13. Barton BE, Murphy TF, Adem P, Watson RA, Irwin RJ and Huang HS: IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells. BMC Cancer 1: 19, 2001. (Pubitemid 38846500)
14. Risberg T, Lund E, Wist E, Kaasa S and Wilsgaard T: Cancer patient use of nonproven therapy: 5-year follow-up study. J Clin Oncol 16: 6-12, 1998.
15. Eisberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR and Delbanco TL: Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 328: 246-252, 1993.
16. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M and Kessler RC: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280: 1569-1575, 1998.
17. Chen S: In vitro mechanism of PC-SPEC. Urology 58 (suppl 2A): 28-35, 2001.
18. Darzykiewicz Z, Traganos F, Wu JM and Chen S: Chinese herbal mixture PC-SPES in treatment of prostate cancer. Int J Oncol 17: 729-736, 2001.
19. DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM, Zhu BT, Spaulding H, Goodin S, Toledano MB, Hait WN and Gallo MA: Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 339: 785-791, 1998.
20. Taille A, Hayek OR, Buttyan R, Bagiella E, Burchardt M and Katz AE: Effects of a phytotherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int 84: 845-850, 1999. (Pubitemid 29500054)
21. Moyad MA, Pienta KJ and Montie JE: Use of PC-SPES, a commercially available supplement for prostate cancer, in a patient with hormone-naive disease. Urology 54: 319-323, 1999.
22. Hsieh T, Chen SS, Wang X and Wu JM: Regulation of androgen receptor (AR) and prostate specific antigen (PSA) expression in the androgen-responsive human prostate LNCaP cells by ethanolic extracts of the Chinese herbal preparation, PC-SPES. Biochem Mol Biol Int 42: 535-544, 1997.
23. Hsieh TC, Ng C, Chang CC, Chen SS, Mittleman A and Wu JM: Induction of apoptosis and down-regulation of bcl-6 in mutu I cells treated with ethanolic extracts of the Chinese herbal supplement PC-SPES. Int J Oncol 13: 1199-1202, 1998.
24. Kubota T, Hisatake J, Hisatake Y, Said JW, Chen SS, Holden S, Taguchi H and Koeffler HP: PC-SPES: a unique inhibitor of proliferation of prostate cancer cells in vitro and in vivo. Prostate: 42: 163-171, 2000.
25. Tiwari RK, Geliebter J, Garikapaty VP, Yedavelli SP, Chen S and Mittelman A: Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer. Int J Oncol 14: 713-719, 1999.
26. de la Taille A, Buttyan R, Hayek O, Bagiella E, Shabsigh A, Burchardt M, Burchardt T, Chopin DK and Katz AE: Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 164: 1229-1234, 2000.
27. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M and Reese DM: Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18: 3595-3603, 2000.
28. Yang Y, Ikezoe T, Saito T, Kobayashi M, Koeffler HP and Taguchi H: Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/ c-Jun/AP-1 signaling. Cancer Sci 95: 176-180, 2004. (Pubitemid 38404320)
29. Ikezoe T, Chen SS, Yang Y, Heber D, Taguchi H and Koeffler HP: PC-SPES: Molecular mechanism to induce apoptosis and down-regulate expression of PSA in LNCaP human prostate cancer cells. Int J Oncol 23: 1461-1470, 2003.
30. Liu JJ, Huang RW, Lin DJ, Peng J, Zhang M, Pan X, Hou M, Wu XY, Lin Q and Chen F: Ponicidin, an ent-kaurane diterpenoid derived from a constituent of the herbal supplement PC-SPES, Rabdosia rubescens, induces apoptosis by activation of caspase-3 and mitochondrial events in lung cancer cells in vitro. Cancer Invest 24: 136-148, 2006.
31. Sartippour MR, Seeram NP, Heber D, Hardy M, Norris A, Lu Q, Zhang L, Lu M, Rao JY and Brooks MN: Rabdosia rubescens inhibits breast cancer growth and angiogenesis. Int J Oncol 26: 121-127, 2005.
32. Ikezoe T, Chen SS, Tong XJ, Heber D, Taguchi H and Koeffler HP: Oridonin induces growth inhibition and apoptosis of a variety of human cancer cells. Int J Oncol 23: 1187-1193, 2003.
33. Ikezoe T, Chen SS, Heber D, Taguchi H and Koeffler HP: Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate 49: 285-292, 2001.
34. Barton BE, Murphy TF, Shu P, Huang HF, Meyenhofen M and Barton A: Novel single-stranded oligonucleotides that inhibit signal transducer and activator of transcription 3 induce apoptosis in vitro and in vivo in prostate cancer cell lines. Mol Cancer Ther 3: 1183-1191, 2004.
35. Barton BE, Karras JG, Murphy TF, Barton A and Huang HF: Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol Cancer Ther 3: 11-20, 2004. (Pubitemid 39193674)
36. Sanford DC and Dewille JW: C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells. Prostate 63: 143-154, 2005.